Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ECOSPOR: A RandomizEd, Double Blind, Placebo COntrolled, Parallel Group Study of SER 109 to Prevent Recurrent ClOstRidium Difficile Infection

Trial Profile

ECOSPOR: A RandomizEd, Double Blind, Placebo COntrolled, Parallel Group Study of SER 109 to Prevent Recurrent ClOstRidium Difficile Infection

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 06 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs SER 109 (Primary)
  • Indications Clostridium difficile infections
  • Focus Therapeutic Use
  • Acronyms ECOSPOR
  • Sponsors Seres Therapeutics

Most Recent Events

  • 07 Apr 2020 Results published in the Clinical Infectious Diseases.
  • 08 Oct 2017 Results of this trial and another one (refer CTP: 700247159) assessing gut microbiome changes were presented at the IDWeek 2017
  • 04 May 2017 According to Seres Therapeutics media release, data from this study was presented at the 27th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) meeting.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top